New therapeutic targets in giant-cell arteritis. Considerations based on the current pathogenic model and the availability of new therapeutic agents

Clinical and Experimental Rheumatology

Volumn 26, Issue 3 SUPPL. 49, 2008, Pages

  Lozano, Ester ^a   Segarra, Marta ^a   García Martínez, Ana ^a   Espígol Frigolé, Georgina ^a   Hernández Rodríguez, José ^a   Cid, Maria C ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Biologic therapies; Cytokines; Pathogenesis; Vasculitis

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ALEMTUZUMAB; ATLIZUMAB; CD20 ANTIGEN; CD28 ANTIGEN; CD52 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; FONTOLIZUMAB; GAMMA INTERFERON; IMATINIB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MARIMASTAT; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; RANTES; RITUXIMAB; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

AORTA ANEURYSM; AORTA ARCH SYNDROME; B LYMPHOCYTE; BLOOD VESSEL OCCLUSION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CLAUDICATION; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; GENE EXPRESSION; GIANT CELL ARTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; LYMPHOCYTE DEPLETION; NECROTIZING ARTERITIS; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATIC POLYMYALGIA; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

DRUG DESIGN; GIANT CELL ARTERITIS; HUMANS; POLYMYALGIA RHEUMATICA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 52049114445     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. SALVARANI.C, CANTINI F, BOIARDI L, HUNDER GG: Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261-71.
2. CID MC, GARCÍA-MARTINEZ A, LOZANO E, ESPÍGOL-FRIGOLÉ G, HERNÁNDEZ-RODRÍGUEZ J: Five clinical conundrums in the management of giant cell arteritis. Rheum Dis Clin North Am 2007; 33: 819-34.
3. HOFFMAN GS, CID MC, HELLMANN DB et al.: A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant-cell arteritis. Arthritis Rheum 2002; 46: 1309-18.
4. HOFFMAN GS, CID MC, RENDT-ZAGAR KE et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant-cell arteritis. Ann Intern Med 2007; 146: 621-30.
5. CID MC, FONT C, ORISTRELL J et al.: Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 26-32.
6. GONZÁLEZ-GAY MA, GARCÍA-PORRUA C, LLORCA J et al.: Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000; 79: 283-92.
7. NESHER G, BERKUN Y, MATES M et al.: Risk factors for cranial ischemic complications in gaint-cell arteritis. Medicine (Baltimore) 2004; 83: 114-22.
8. FOROOZAN R, DERAMO VA, BUONO LM et al.: Recovery of visual function in patients with biopsy-proven giant-cell arteritis. Ophthalmology 2003; 110: 539-42.
9. HAYREH SS, ZIMMERMAN B, KARDON RH et al.: Visual improvement with corticosteroid therapy in giant-cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002; 80: 353-67.
10. HAYREH SS, ZIMMERMAN B: Visual deterioration in giant-cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003; 110: 1204-15.
11. LIU GT, GLASER JS, SCHATZ NJ et al.: Visual morbidity in giant-cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994; 101: 1779-85.
12. GARCÍA-MARTÍNEZ A, HERNÁNDEZ-RODRÍGUEZ J, ARGUIS P et al.: Development of aortic aneurysm/dilatation during the follow up of patients with giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008; 59: 422-30.
13. KLEIN RG, HUNDER GG, STANSON AW et al.: Large artery involvement in giant-cell (temporal) arteritis. Ann Intern Med 1975; 83: 806-12.
14. NUENNINGHOFF DM, HUNDER GG, CHRISTIANSON TJH et al.: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis. A population-based study over 50 years. Arthritis Rheum 2003; 48: 3522-31.
15. WILKE WS, HOFFMAN GS: Treatment of corticosteroid-resistant giant-cell arteritis. Rheum Clin Dis North Am 1995; 21: 59-71.
16. PROVEN A, GABRIEL S, ORCES C, O'FALLON M, HUNDER GG: Glucocorticoid therapy in giant-cell arteritis: Duration and adverse outcomes. Arthritis Rheum 2003; 49: 703-8.
17. DELECOEUILLERIE G, JOLY P, COHEN DE LARA A, PAOLAGGI JB: Polymyalgia rheumatica and temporal arteritis: A retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients) Ann Rheum Dis 1988; 47: 733: 9.
18. ANDERSSON R, MALMVALL BE, BENGTSSON BA: Long-term corticosteroid treatment in giant-cell arteritis. Acta Med Scand 1986; 220: 465-9.
19. CID MC, FONT C, COLL-VINENT B, GRAU JM: Large vessel vasculitides. Curr Opin Rheumatol 1998; 10: 18-28.
20. WEYAND CM, GORONZY JJ: Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160-9.
21. HERNÁNDEZ-RODRÍGUEZ J, FONT C, GARCÍA-MARTÍNEZ A et al.: Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatics: Study of a series of 100 patients. Medicine (Baltimore) 2007; 86: 233-41.
22. CID MC, CAMPO E, ERCILLA MG et al.: Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunological activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989; 32: 884-93.
23. MA-KRUPA W, JEON MS, SPOERL S, TEDDER TF, GORONZY JJ, WEYAND CM: Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199: 173-83.
24. WEYAND CM, SCHÖNBERGER J, OPPITZ U, HUNDER NN, HICOK KC, GORONZY JJ: Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 1994; 179: 951-60.
25. WECK KE, DAL CANTO AJ, GOUD JD et al.: Murine gammaherpes virus 68 causes large vessel arteritis in mice lacking interferon-gamma responsiveness: A new model from virus-induced vascular disease. Nat Med 1997; 3: 1346-53.
26. RODRÍGUEZ-PLA A, BOSCH GIL JA, ECHEVARRIA-MAYO JE et al.: No detection of parvovirus B19 or herpesvirus DNA in giant cell arteritis. J Clin Virol 2004; 31: 11-5.
27. ALVAREZ-LAFUENTE A, FERNANDEZ-GUTIERREZ B, JOVER JA et al.: Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis 2005; 64: 780-2.
28. HELWEG-LARSEN J, TARP B, OBEL N, BASLUND B: No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology (Oxford) 2002; 41: 445-9.
29. MA-KRUPA W, DEWAN M, JEON MS, KURTIN PJ et al.: Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002; 161: 1815-23.
30. VOGL T, TENBROCK K, LUDWIG S et al.: MRP8 and MRP14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-9.
31. FOELL D, HERNÁNDEZ-RODRÍGUEZ J, SÁNCHEZ M, VOGL T,CID MC, ROTH J: Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J Pathol 2004; 204: 311-6.
32. HAJJ-ALI R, HAMILTON T, LEE M et al.: Temporal artery expression profiles may predict conditions necessary for developing giant-cell arteritis. Arthritis Rheum 2006; 54 (Suppl.): S756.
33. CID MC, HOFFMAN MP, HERNÁNDEZ-RODRÍGUEZ J et al.: Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology (Oxford) 2006; 45: 1356-63.
34. BOSSHART H, HEINZELMANN MT Targeting bacterial endotoxin: two sides of a coin. Ann NY Acad Sci 2007; 1096: 1-17.
35. STOLL LL, DENNING GM, WEINTRAUB NL: Endotoxin, TLR-4 signaling and vascular inflammation. Potential therapeutic targets in cardiovascular disease. Curr Pharmacol Des 2006; 12: 4229-45.
36. BRACK A, GEISLER A, MARTÍNEZ-TABOADA VM, YOUNGE BR, GORONZY JJ, WEYAND CM: Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997; 3: 530-43.
37. MAGLIOCCA JF, KNECHTLE SJ: The evolving role of alemtuzumab (CAMPATH-1H) for immunosuppressive therapy in organ transplantation. Transplant Int 2006; 19: 705-14.
38. WALSH M, CHAUDHRYA, JAYNE DR: Long-term follow-up of relapsing/ refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2007 Nov 29.
39. MARTÍNEZ-TABOADA VM, BRACK A, HUNDER GG, GORONZY JJ, WEYAND CM: The inflammatory infiltrate in giant cell arteritis selects against B lymphocytes. J Rheumatol 1996; 23: 1011-4.
40. BHATIA A, ELL PJ, EDWARDS JC: Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005; 64: 1099-100.
41. KREMER JM, GENANT HK, MORELAND LW: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006; 144: 865-76
42. SALLIOT C, DOUGADOS M, GOSSEC L: Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2008 Jan 18. [Epub ahead of print]
43. WEYAND CM, HICOK KC, HUNDER GG, GORONZY JJ: Tissue cytokine pattern in patients with polymyalgia rheumatica and giant-cell arteritis. Ann Intern Med 1994; 121: 484-91.
44. BRÜHL H, VIELHAUER V, WEISS M, MACK H, SCHLÖNDORFF D, SEGERER S: Expression of DARC, CXCR3 and CCR5 in giant cell arteritis. Rheumatology (Oxford) 2005; 44: 309-13.
45. WEYAND CM, KAISER M, YANG H, YOUNGE B, GORONZY JJ: Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 457-66.
46. GHOSH S, CHAUDHARY R, CARPANI M, PLAYFORD R: Interfering with interferons in inflammatory bowel diseases. Gut 2006; 55: 1071-3.
47. HOMMES DW, MIKHAJLOVA TL, STOINOV S et al.: Fontolizumab, a humanised anti-IFNγ antibody demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006; 55: 1131-7.
48. SHIMIZU K, SHICHIRI M, LIBBY P, LEE RT, MITCHELL RN: Th2-predominant inflammation and blockade of IFN-gamma signalling induce aneurysms in allografted aortas. J Clin Invest 2004; 114: 300-8.
49. WORBS T, MEMPEL TR, BÖLTER J, VON ADRIAN VH, FOISTER R: CCR7 ligands stimulate the intranodal mobility of T lymphocytes in vivo. J Exp Med 2007; 204: 489-95.
50. HU X, PARK-MIN KH, HO HH, IVASHKIV LB: IFNγ primed macrophages exhibit increased CCR2-dependent migration and altered IFNγ responses mediated by Stat1. J Immunol 2005; 175: 3637-47.
51. KUHMANN SE, HARTLEY O: TargetingAchemokine receptors in HIV: a status report. Annu Rev Pharmacol Toxicol 2008; 48: 425-61.
52. VIOLA A, LUSTER AD: ChemokRnes and their receptors:drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008; 48: 171-97.
53. CID MC, BIELSA I, COLL-VINENT B: Endothelial cell adhesion molecules. In Inflammatory diseases of blood vessels. Ed. GS Hoffman and CM Weyand. 2001. Marcel Dekker, Inc. New York-Basel. pp 13-28.
54. CID MC, VILARDELL C: Tissue targeting and disease patterns in systemic vasculitis. Best Pract Res Clin Rheumatol 2001: 259-79.
55. LEY K, LAUDANNA C, CYBULSKI MI, NOURSHARGH S: Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-89.
56. LAFFON A, GARCÍA-VICUÑA R: Humbría A et al.: Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest 1991; 88: 546-52.
57. YEDNOCK TA, CANNONC, FRITZ LC, SÁNCHEZ-MADRID F, STEINMAN L, KARIN N: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-6.
58. ESPARZA J, VILARDELL C, CALVO J et al.: Fibronectin up-regulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood 1999; 94: 2754-66.
59. SEGARRA M, VILARDELL C, MATSUMOTO K et al.: Dual function of focal adhesión kinase in regulating integrin-induced MMP2 and MMP9 release by human T lymphoid cell lines. FASEB J 2005; 19: 1875-7.
60. CID MC, CEBRIÁN M, FONT C et al.: Cell adhesion molecules in the development of inflammatory infiltrates in giant-cell arteritis. Inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000; 43: 184-94.
61. SEGARRA M, GARCÍA-MARTÍNEZ A, SÁNCHEZ M et al.: Leukocyte integrin alpha 4 is associated with gelatinase (MMP2 and MMP9) and MMP14 expression and activation in GCA lesions. Arthritis Rheum 2006; 54 (Suppl): S578-9.
62. SANDBORN WJ: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25.
63. POLMAN CH, O'CONNOR PW, HAVRDOVA E et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
64. CORTIJO J, SANZ MJ, IRANZO A et al.: A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. Br J Pharmacol 2006; 147: 661-70.
65. BERGER JR: Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 2006; 65 (Suppl. 3): III48-53.
66. CID MC: Endothelial cell biology, perivascular inflammation, and vasculitis. Cleve J Med 2002; 62 (Suppl. 2): 45-50.
67. FELDMANN M, MAINI RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
68. HERNÁNDEZ-RODRÍGUEZ J, SEGARRA M, VILARDELL C et al.: Tissue production of pro-inflammatory cytokines (IL-1beta, TNF-alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43: 294-301.
69. HERNÁNDEZ-RODRÍGUEZ J, GARCÍA-MARTÍNEZ A, CASADEMONT J et al.: A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002; 47: 29-35.
70. GARCÍA-MARTÍNEZ A, HERNÁNDEZ-RODRÍGUEZ J, SEGARRA M et al.: Clinical relevance of persistenly elevated circulating cytokines (TNFα and IL-6) in the long-term follow-up of patients with giant-cell arteritis (GCA). Arthritis Rheum 2006; 54: S763.
71. HOFFMAN GS, MERKEL PA, BRASSINGTON RD, LENSCHOW DJ, LIANG P: Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50: 2296-304.
72. MARTÍNEZ-TABOADA VM, RODRÍGUEZ-VALVERDE V, CARREÑO L et al.: A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625-30.
73. CHURCH LD, CHURCHMAN SM, HAWKINS PN, MCDERMOTT MF: Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol 2006; 27: 494-508.
74. NICKLIN MJ, HUGHES DE, BARTON JL, URE JM, DUFF GW: Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000; 191: 303-12.
75. SHEPHERD J, NICKLIN MJ: Elastic-vessel arteritis in interleukin-1 receptor antagonist-deficient mice involves effector Th1 cells and requires interleukin-1 receptor. Circulation 2005; 111: 3135-40.
76. DASGUPTA B, PANAYI GS: Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990; 29: 456-8.
77. OHSUGI Y: Recent advances in immunopathophysiology ofAinterleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 2007; 30: 2001-6.
78. NISHIMOTO N, NAKAHARA H, YOSHIO-HOSHIMO N, MIMA T: Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor anti-body. Arthritis Rheum 2008; 58: 1197-200.
79. GARCÍA-MARTÍNEZ A, LOZANO E, SEGARRA M et al.: Human temporal artery culture on Matrigel: A useful method for preclinical assessment of functional changes after intervention. Arthritis Rheum 2007; 56 (Suppl.): S497.
80. HERNÁNDEZ-RODRÍGUEZ J, SEGARRA M, VILARDELL C et al.: Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107: 2428-34.
81. CID MC, HERNÁNDEZ-RODRÍGUEZ J, ESTEBAN MJ et al.: Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002; 106: 1664-71.
82. NORDBORG C,LARSSON K, NORDBORG E: Stereological study of neovascularization in temporal arteritis. J Rheumatol 2006; 33: 2020-5.
83. KAISER M, YOUNGE B, BJÖRNSSON J, GORONZY JJ, WEYAND CM: Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999; 155: 765-74.
84. LOZANO E, SEGARRA M, GARCÍA-MARTÍNEZ A, HERNÁNDEZ-RODRÍGUEZ J, CID MC: Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant-cell arteritis. Ann Rheum Dis 2007 Jun 21;
85. BAINBRIDGE J, SIVAKUMAR B, PALEOLOG E: Angiogenesis as a therapeutic target in arthritis: Lessons from oncology. Curr Pharm Des 2006; 12: 2631-44.
86. CAÑETE JD, PABLOS JL, SANMARTÍ R et al.: Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004; 50: 1636-41.
87. ESTEBAN MJ, FONT C, HERNÁNDEZ-RODRÍGUEZ J et al.: Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathological findings in a series of twenty-eight patients. Arthritis Rheum 2001; 44: 1387-95.
88. GARCÍA-PORRÚA C, PEGO-REINOSA R, ARMESTO V, GONZÁLEZ-GAY MA: Neovascularization around the optic nerve in giant cell arteritis. Arthritis Rheum 2003; 49: 737-8.
89. RUEDA B, LÓPEZ-NEVOT MJ, GARCÍA-PORRÚA C, MARTÍN J, GONZÁLEZ-GAY MA: A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005; 32: 1737-41.
90. LIE JT: Aortic and extracranial large vessel giant ceAl arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995; 24: 422-31.
91. SEGARRA M, GARCÍA-MARTÍNEZ A, SÁNCHEZ M et al.: Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 2007; 66: 1429-35.
92. SEGARRA M, SÁNCHEZ M, LOZANO E et al.: Matrix metalloelastase (MMP12) expresión in giant-cell arteritis lesions. Ann Rheum Dis 2007; 66 (Suppl.): 5383-4.
93. MANICONE AM, MCGUIRE JK: Matrix metalloproteases as modulators of inflammation. Semin Cell Dev Biol 2008; 19: 34-41.
94. ESPARZA J, KRUSE M, LEE J, MICHAUD M, MADRI JA. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J 2004; 18: 1682-91.
95. FURMANIAK-KAZMIERCZAK E, CRAWLEY SW, CARTER RL: Formation of extracellular matrix-digesting invadopodia by primary aortic smooth muscle cells. Circ Res 2007; 100: 1328-36.
96. CHUNG AW, YANG HH, RADOMSKI MW, VAN BREEMEN C: Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res 2008; 102:e 73-85.
97. BAXTER BT, TERRIN MC, DALMAN RL: Medical management of small abdominal aortic aneurysms. Circulation 2008; 117: 1883-9.
98. SUJOBERT P, FARDET L, MARIE I et al.: Mesenteric ischemia in giant cell arteritis: 6 cases and a systematic review. J Rheumatol 2007; 34: 1727-32.
99. DRUKER BJ,GUILHOT F, O'BRIEN SG: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
100. BRACK A, RITTNER HL, YOUNGE BR, KALTSCHMIDT C, WEYAND CM, GORONZY JJ: Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997; 99: 2842-50.
101. WARRINGTON KJ, MATTESON EL: Management guidelines and outcome measures in giant-cell arteritis (GCA). Clin Exp Rheumatol 2007; 25 (Suppl. 47): 137-41.
102. DASGUPTA B, HASSAN N: British Society for Rheumatology guidelines group. Giant cell arteritis: Recent advances and guidelines for management. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S62-5.
103. MAKSIMOWICZ-MCKINNON K, HOFFMAN GS: Large vessel vasculitis. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S58-9.